Evaxion to Present New Biomarker Data for AI-Designed Cancer Vaccine EVX-01 at SITC 2025 Annual Meeting

Evaxion will present new biomarker and immune data for its AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The data will be the latest addition to EVX-01's strong data package, which includes one-year interim data from the phase 2 trial. Two-year clinical efficacy data from the trial will be presented at the European Society for Medical Oncology (ESMO) 2025 congress on October 17, 2025.

Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company, will present new biomarker and immune data for its AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The data will be presented as a poster (Abstract #605, Poster #605) titled "Immune correlates of clinical response following treatment with the personalized cancer vaccine EVX-01 and Pembrolizumab in advanced melanoma patients," by Michail Angelos Pavlidis on November 7, 2025, from 5:10–6:35 p.m. ET. This presentation is part of the ongoing phase 2 trial of EVX-01 in combination with KEYTRUDA® (pembrolizumab) for advanced melanoma patients.

The two-year clinical efficacy data from the same phase 2 trial will be presented orally at the European Society for Medical Oncology (ESMO) 2025 congress on October 17, 2025. These presentations will add to the strong data package for EVX-01, which includes convincing one-year interim data from the phase 2 trial. The poster presentation at SITC 2025 will provide insights into the immune correlates and biomarkers associated with the clinical response to EVX-01 and KEYTRUDA®, while the oral presentation at ESMO 2025 will offer two-year efficacy results.

EVX-01 is designed using Evaxion's AI-Immunology™ platform, which tailors the vaccine to each patient's unique tumor profile and immune characteristics. The vaccine engages the patient's immune system to fight cancer by mounting a targeted response against tumors. In clinical trials, EVX-01 has demonstrated overall response rates of 69% and 67% in patients with advanced melanoma, highlighting its potential efficacy Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting^[1].

The presentations at SITC 2025 and ESMO 2025 will provide a formal opportunity for peer review and independent scrutiny of the data, which can enhance the clinical credibility and partner engagement for EVX-01. Investors and financial professionals should monitor these presentations for concrete data and insights into the vaccine's mechanism of action and patient benefits .